Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02694978 · ClinicalTrials.gov registry record · Phase 3
A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
A Phase 3 study, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,014
- Enrollment target
NCT02694978: Completed Phase 3 study, sponsored by AMAG Pharmaceuticals.
NCT02694978 is a Phase 3 study that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 2,014 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (161% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02694978, a Phase 3 study, has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,014 participants
- Enrollment target
Study Summary
To evaluate the safety of 1.020 grams (g) of intravenous (IV) ferumoxytol compared to 1.500 g of IV ferric carboxymaltose (FCM).
Primary Outcome
All IV iron formulations carry some risk of serious hypersensitivity reactions or anaphylaxis. Signs and symptoms potentially representing hypersensitivity were recorded and adjudicated by a blinded Clinical Events Committee (CEC). Hypotension is defined as a \>30% drop in systolic blood pressure from baseline or decrease of \>20 mmHg for systolic blood pressure. Statistical analysis was only performed on composite data. A summary of serious and all other non-serious adverse events regardless o
Interventions
- DRUG Ferumoxytol
- DRUG FCM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,014 participants |
| Start Date | 2016-02-29 |
| Est. Completion | 2017-07-17 |
| Phase | Phase 3 |
What the finished NCT02694978 record still lists
NCT02694978 is an interventional study that assigns participants to a tested intervention. Its 2,014 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (161% higher).
The record links to 0 conditions, and to 2 interventions - of which Ferumoxytol is the first listed.
NCT02694978 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02694978 about?
NCT02694978 is a clinical study titled "A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)". To evaluate the safety of 1.020 grams (g) of intravenous (IV) ferumoxytol compared to 1.500 g of IV ferric carboxymaltose (FCM).
What is the current status of trial NCT02694978?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,014 participants. The study started on 2016-02-29. Estimated completion is 2017-07-17.
What interventions are being tested in trial NCT02694978?
The interventions under investigation include: Ferumoxytol (DRUG), FCM (DRUG).
Who is sponsoring clinical trial NCT02694978?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02694978's enrollment target sits among peer trials
2,014 100th of 2000 higher than 1,901 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04604509 · 2,010 participants · Phase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
- NCT04100564 · 2,009 participants · NA
LITES Task Order 0005 Prehospital Airway Control Trial (PACT)
- NCT05059444 · 2,020 participants
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI